Wendy Stock
Section of Hematology / Oncology
Professor of Medicine
Anjuli Seth Nayak Professor in Leukemia; Director, Leukemia Program
Referring Physician Access Line: 1-877-DOM-2730


BS1976University of IllinoisBiology
MA1978University of CaliforniaZoology
MD1985Rush Medical College 
Residency1988The University of ChicagoInternal Medicine
Fellowship1993The University of ChicagoHematology/Oncology

Academic Interests

Dr. Stock is involved in clinical and laboratory efforts directed towards improving treatment for adult leukemias and myelodysplastic syndromes. She is focused on the development and conduct of novel therapeutic trials for these diseases, both at the institutional and national level. Her laboratory focuses on studies to determine the clinical significance of the molecular detection and monitoring of minimal residual disease (MRD) states following treatment and is the national reference laboratory for several of these studies. She is also developing novel technology to measure tyrosine kinase activity in leukemia cells as a method for predicting response to treatment with novel targeted kinase inhibitors.

Clinical Interests

Acute myeloid leukemia, acute lymphoblastic leukemia,chronic lymphocytic leukemia,chronic myeloid leukemia,myelodysplastic syndromes,stem cell transplantation - allogeneic and autologous

Representative Publications

  1. van Besien K., Smith S., Anastasi J., Thirman M., Odenike O., Stock, W. Irresversible myelosuppression after fludarabine-melphalan conditioning. Observations in patients with graft rejection. Blood 103:4373-4374, 2004
  2. Marcucci G, Stock W, Dai G, Klisovic MI, Maharry K, Shen T, Liu S, Sher DA, Lucas D, Zwiebel A, Larson RA, Caligiuri MA, Bloomfield CD, Chan KK, Grever MR, Byrd JC G3139, a BCL-2 antisense oligo-nucloetide, in AML. Ann Hematol, 83, Suppl 1:S93-94, 2004
  3. van Besien K., Keralavarma, B., Devine, S., Stock, W. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 15:1317-1325, 2001
  4. Stock, W., Estrov, Z. Studies of minimal residual disease in acute lymphoblastic leukemia. Hematology/Oncology Clinics of North America 14: 1289-1305, 2000
  5. Stock, W., Tsai, D., Golden, C., Rankin, C., Sher, D., Slovak, M. L., Pallavachini, M., Boldt, D.H. Cell cycle regulatory gene abnormalities are important determinants of leukemogenesis and disease biology in adult acute lymphoblastic leukemia (ALL). Blood 95: 2364-2371,2000

More Information

For more information about Dr. Wendy Stock publications and research collaborations , please click here